Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | CTSK | P43235 | 10/20 | 0.57 |
| ▸ | CTSB | P07858 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 2/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | CTSH | P09668 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094506 | 1.00 | ATM (0.62) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL7094 | 1.00 | ATM (0.62) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL9929938 | 0.92 | CTSK (0.61) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL19924528 | 0.92 | ATM (0.54) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL598263 | 0.92 | CTSK (0.61) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL8523201 | 0.92 | CTSK (0.61) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL2736190 | 0.91 | ATM (0.61) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL12137049 | 0.91 | ATM (0.61) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL20204705 | 0.90 | CTSS (0.65) | ATMCTSKCTSBCTSLCTSS | |
| SCHEMBL22962275 | 0.90 | CTSS (0.65) | ATMCTSKCTSBCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | RELYPSA, INC. (US) | 2019-04-30 | — | — | US | claimed |
| US-20170258825-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. | 2017-09-14 | — | — | US | claimed |
| EP-2998329-A2 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2016-03-23 | — | — | EP | claimed |
| US-20160051576-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2016-02-25 | — | — | US | claimed |
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | claimed |
| EP-2539380-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2013-01-02 | — | — | EP | claimed |
| WO-2011106542-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2011-09-01 | — | — | WO | claimed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | claimed |
| US-RE36718-E | 3-AMINO-1-NITRO-4-PHENYL-2-BUTANOL DERIVATIVES | KANEKA CORPORATION (JP) | 2000-05-30 | — | — | US | claimed |
| US-5616726-A | AN 3-AMINO-1-NITRO-4-PHENYL-2-BUTANOL BY ADDING NITROMETHANE STEREOSELECTIVELY IN THE PRESENCE OF A BASE TO AN OPTICAL ACTIVE AMINOALDEHYDE; CHEMICAL INTERMEDIATES FOR DRUGS; E.G. THE ANTICARCINOGENIC AGENT, BESTATIN | KANEKA CORPORATION (JP) | 1997-04-01 | — | — | US | claimed |
| EP-0657415-A1 | OPTICALLY ACTIVE AMINO ALCOHOL DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | KANEKA CORPORATION (JP) | 1995-06-14 | — | — | EP | claimed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12454502-B2 | Synthesis of deuterated aldehydes | ARIZONA BOARD OF REGENTS ON BEHALF OF ATHE UNIVERSITY OF ARIZONA (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| EP-4551555-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-4826815-A | HYPOTENSIVE | ABBOTT LABORATORIES (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0260668-A2 | Separation of diastereomers | WARNER-LAMBERT COMPANY (US) | 1988-03-23 | — | — | EP | disclosed |
| US-4681972-A | Separation of diastereomers | WARNER-LAMBERT COMPANY (US) | 1987-07-21 | — | — | US | disclosed |
| US-4657931-A | RENIN-INHIBITING | G. D. SEARLE & CO. (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0202577-A2 | N(Acyldipeptidyl)-aminoglycols | G.D. Searle & Co. (US) | 1986-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051576-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, GPBAR1 | ATM 2057/4885CTSK 4156/4885CTSB 4421/4885 |
| US-12454502-B2 | Synthesis of deuterated aldehydes | ADH1C, ADH1A, CBR1 | ATM 1452/4885CTSK 2382/4885CTSB 3253/4885 |
| US-20170258825-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, SLC10A1 | ATM 1814/4885CTSK 3267/4885CTSB 3144/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | ATM 3356/4885CTSK 2087/4885CTSB 1625/4885 |
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | NR1H4, SLC10A2, GPBAR1 | ATM 2057/4885CTSK 4156/4885CTSB 4421/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | ATM 1205/4885CTSK 1259/4885CTSB 1263/4885 |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | ATM 523/4885CTSK 3934/4885CTSB 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.